卡瑞利珠单抗联合化疗治疗局部晚期食管癌的效果  

Efficacy of camrelizumab combined with chemotherapy in the treatment of locally advanced esophageal cancer

作　　者：徐赟[1] 袁征[2] 沙金平[3] 邓琳琳[4] 贾会文[5] Xu Yun;Yuan Zheng;Sha Jinping;Deng Linlin;Jia Huiwen(Department of Oncology,Nanyang Central Hospital,Nanyang 473000,China;Department of Pathology,Nanyang Central Hospital,Nanyang 473000,China;Department of Gastroenterology,Nanyang Central Hospital,Nanyang 473000,China;Teching and Research Section of Gynecology and Pediatrics,Department of Clinical Medicine,Nanyang Medical College,Nanyang 473000,China;Department of General Surgery,Nanyang Central Hospital,Nanyang 473000,China)

机构地区：[1]南阳市中心医院肿瘤内科,南阳473000 [2]南阳市中心医院病理科,南阳473000 [3]南阳市中心医院消化内科,南阳473000 [4]南阳医学高等专科学校临床医学系妇儿教研室,南阳473000 [5]南阳市中心医院普外科,南阳473000

出　　处：《中国实用医刊》2024年第24期101-103,共3页Chinese Journal of Practical Medicine

摘　　要：目的探讨卡瑞利珠单抗联合化疗治疗局部晚期食管癌的疗效及其影响因素。方法回顾性抽取2021年1月至2023年7月南阳市中心医院收治的局部晚期食管鳞癌患者96例, 依据治疗方案分为对照组(56例, 给予单纯化疗)和研究组(40例, 给予卡瑞利珠单抗联合化疗)。比较两组临床疗效、不良反应发生率及1年生存率。结果研究组疾病控制率(90.0%, 36/40)高于对照组(71.4%, 40/56), P<0.05。治疗后, 两组不良反应发生率比较差异未见统计学意义(P>0.05)。研究组1年生存率(85.0%, 34/40)高于对照组(66.1%, 37/56), P<0.05。结论卡瑞利珠单抗联合化疗对局部晚期食管癌的疗效较佳, 安全性较高, 能改善患者预后。Objective To investigate the efficacy of camrelizumab combined with chemotherapy in the treatment of locally advanced esophageal cancer.MethodsA total of 96 patients with locally advanced esophageal squamous cell carcinoma admitted to Nanyang Central Hospital from January 2021 to July 2023 were retrospectively selected,and they were divided into the control group(56 cases,treated by chemotherapy alone)and the study group(40 cases,treated with camrelizumab combined with chemotherapy)according to the treatment plan.The clinical efficacy,incidence of adverse reactions and 1-year survival rate were compared between the two groups.ResultsThe disease control rate of the study group(90.0%,36/40)was higher than that of the control group(71.4%,40/56),P<0.05.There was no significant difference in the incidence of adverse reactions between the two groups after treatment(P>0.05).The 1-year survival rate of the study group(85.0%,34/40)was higher than that of the control group(66.1%,37/56),P<0.05.ConclusionsCamrelizumab combined with chemotherapy has better efficacy and higher safety in the treatment of locally advanced esophageal cancer,and it can improve the prognosis.

关 键 词：卡瑞利珠单抗 化疗 局部晚期食管癌 病理完全缓解 

分 类 号：R73[医药卫生—肿瘤]